1061 — Essex Bio-Technology Income Statement
0.000.00%
Last trade - 00:00
- HK$1.24bn
- HK$1.02bn
- HK$1.71bn
- 95
- 94
- 28
- 88
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,279 | 978 | 1,638 | 1,318 | 1,707 |
Cost of Revenue | |||||
Gross Profit | 1,033 | 794 | 1,396 | 1,189 | 1,539 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 921 | 726 | 1,234 | 1,046 | 1,348 |
Operating Profit | 359 | 252 | 404 | 272 | 359 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 352 | 251 | 394 | 260 | 346 |
Provision for Income Taxes | |||||
Net Income After Taxes | 303 | 219 | 346 | 225 | 275 |
Net Income Before Extraordinary Items | |||||
Net Income | 303 | 219 | 346 | 225 | 275 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 309 | 225 | 350 | 229 | 279 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.512 | 0.383 | 0.582 | 0.439 | 0.479 |
Dividends per Share |